EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseVergleichsstudie

The long-term cardiovascular benefits of metabolic and bariatric surgery versus pharmacological therapies in patients with type 2 diabetes and obesity: a systematic review and meta-analysis

Junle Tong, Yaoquan Cao, Yu Han, Wenbo Wang, Changyan Zhu, Hong Yuan, Shaihong Zhu, Yao Lu, Liyong Zhu

Surgery for Obesity and Related Diseases · 2026-11 · 22 (11) · 1257-1267

DOI: 10.1016/j.soard.2026.06.012 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Surgery for Obesity and Related Diseases, 2026-11. Verfasst von Junle Tong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bariatric and Metabolic Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Bariatric Surgery, Cardiovascular Diseases, Obesity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hunan Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Type 2 diabetes (T2D) and obesity are major global public health challenges and are strongly associated with increased cardiovascular morbidity and mortality. Metabolic and bariatric surgery (MBS) and pharmacological therapies, including glucagon-like peptide-1 receptor agonists, have demonstrated cardiovascular benefits in patients with T2D and obesity. However, the comparative effects of MBS and pharmacological therapies on cardiovascular outcomes in this population remain unclear. OBJECTIVES: To systematically compare the cardiovascular benefits of MBS versus pharmacological therapies in patients with T2D and obesity. SETTING: University-affiliated hospital, China. METHODS: We systematically searched multiple databases for controlled studies published up to April 12, 2025. We compared the efficacy of MBS versus pharmacological therapies in patients with T2D and obesity across multiple outcomes, focusing on major adverse cardiovascular events (MACE), and its relevant indicators, including systolic blood pressure (SBP), diastolic blood pressure (DBP), hemoglobin A1c (HbA1c), fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and body mass index (BMI). RESULTS: A total of 15 studies were included. MBS demonstrated superior effects compared with pharmacological therapies in reducing MACE and improving most cardiovascular risk factors. This benefit remained significant at 5years (odds rati = .66, 95% confidence interval: .59 to .73) and continued to increase over time. Regarding cardiovascular risk factors, MBS showed greater improvements than pharmacological therapies during follow-up periods of 0-1 year (HbA1c, TC, LDL-C), 0-2 years (TG, HDL-C), 2-5 years (SBP, DBP), and 0-5 years (FBG). CONCLUSIONS: In patients with T2D and obesity, MBS demonstrates significant and sustained superiority over pharmacological therapies in improving cardiovascular outcomes. The advantage of surgical intervention over pharmacological intervention in modifying cardiovascular risk factors exhibits heterogeneity based on follow-up duration, BMI category, and the drug class.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Bariatric SurgeryCardiovascular DiseasesObesityHypoglycemic AgentsHumans

Stichwörter der Autor:innen

Major adverse cardiovascular eventsMeta-analysisMetabolic and bariatric surgeryPharmacological therapiesType 2 diabetes

Substanzen

Hypoglycemic Agents

Autor:innen und Institutionen

  • Department of Bariatric and Metabolic Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
  • Clinical Research Center, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China; Department of Cardiology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
  • Clinical Research Center, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China; Department of Cardiology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China; Furong…
  • Department of Bariatric and Metabolic Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China; Furong Laboratory, Central South University, Changsha, Hunan, China. Electronic address: zly…

Förderung

  • National Natural Science Foundation of China
  • Hunan Provincial Natural Science Foundation

Zitieren

APA

Tong, J., Cao, Y., Han, Y., Wang, W., Zhu, C., Yuan, H., Zhu, S., Lu, Y., & Zhu, L. (2026). The long-term cardiovascular benefits of metabolic and bariatric surgery versus pharmacological therapies in patients with type 2 diabetes and obesity: a systematic review and meta-analysis. Surgery for Obesity and Related Diseases, 22(11), 1257-1267. https://doi.org/10.1016/j.soard.2026.06.012

Vancouver

Tong J, Cao Y, Han Y, Wang W, Zhu C, Yuan H, et al. The long-term cardiovascular benefits of metabolic and bariatric surgery versus pharmacological therapies in patients with type 2 diabetes and obesity: a systematic review and meta-analysis. Surgery for Obesity and Related Diseases. 2026;22(11):1257-1267. doi:10.1016/j.soard.2026.06.012

BibTeX
@article{Tong2026,
  author = {Tong, Junle and Cao, Yaoquan and Han, Yu and Wang, Wenbo and Zhu, Changyan and Yuan, Hong and Zhu, Shaihong and Lu, Yao and Zhu, Liyong},
  title = {The long-term cardiovascular benefits of metabolic and bariatric surgery versus pharmacological therapies in patients with type 2 diabetes and obesity: a systematic review and meta-analysis},
  journal = {Surgery for Obesity and Related Diseases},
  year = {2026},
  volume = {22},
  number = {11},
  pages = {1257--1267},
  doi = {10.1016/j.soard.2026.06.012}
}
Kostenlos starten →